Updated:
Scholar Rock Holding Corp
Scholar Rock develops antibody therapies for neuromuscular diseases. It announced U.S. approval of ISEMBYLD for specified SMA patients in September 2026.
Overview
Scholar Rock Holding Corporation is a biopharmaceutical company focused on spinal muscular atrophy and other rare neuromuscular diseases. Its platform develops monoclonal antibodies that selectively target latent forms of growth factors, including an anti-myostatin pipeline. On September 11, 2026, the company announced FDA approval of ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy in adults and children aged two and older who are receiving an SMN2-targeted treatment. Its other development programs remain distinct from that approved indication. For fiscal 2025, ended December 31, 2025, the company originally reported USD 0 million in revenue and a net loss of USD 377.939 million.
Company overview
- Legal name
- SCHOLAR ROCK HOLDING CORPORATION
- Classification
- Public company
- Industry (SIC)
- 2836 — Biological Products, (No Diagnostic Substances)
- Headquarters
- Cambridge, MA, United States
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 0001727196
Financials
Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.
| Fiscal year | Period end | Revenue | Net income | Total assets | Cash and equivalents | Operating cash flow |
|---|---|---|---|---|---|---|
| FY2025USD | $0 | -$377.9M | $404.3M | $323.5M | -$300.0M | |
| FY2024USD | — | -$246.3M | $474.9M | $177.9M | -$200.9M | |
| FY2023USD | — | -$165.8M | $311.0M | $101.9M | -$145.2M | |
| FY2022USD | $33.2M | -$134.5M | $358.2M | $103.3M | -$132.7M |
FY2025. Net income: shown as originally filed; later filings report different values for the same periods.
FY2024. Net income: shown as originally filed; later filings report different values for the same periods.
FY2023. Net income: shown as originally filed; later filings report different values for the same periods.
Recent SEC filings
| Form | Filed | Period | Filing |
|---|---|---|---|
| 8-K | FORM 8-K | ||
| 8-K | FORM 8-K | ||
| 8-K | FORM 8-K | ||
| 10-Q | 10-Q | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 10-Q | 10-Q | ||
| 8-K | 8-K | ||
| DEF 14A | DEF 14A | ||
| 8-K | FORM 8-K | ||
| 10-K | 10-K | ||
| 8-K | 8-K |
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Research Scholar Rock Holding Corp in Altss
Track this company’s investors, transactions and relationships in Altss.